Fig. 4.
![Fig. 4. Immunotherapy of lymphoma-bearing mice with BsAb directed to Id, MHC II, or CD19 on the tumors. / Groups of 5 huCD64+ age-matched mice received a treatment schedule as shown in Figure 3. Treatment was as indicated: PBS (●); [huCD64 × CD19] (▵); [huCD64 × MHC II] (■); [huCD64 × Id] (○). Survival was recorded daily. In the A31 model all treatment modalities resulted in a statistically significant increase in survival over PBS-treated controls (P < .02), though only [huCD64 × Id] BsAb–treated cohorts showed long-term survival. Similar results were obtained in at least 3 similar experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347004.jpeg?Expires=1735835337&Signature=vVtD2toqv6EbpqaNwhhRxXX0BW8VGMqWOuNFWqO9YqCkU1cDdJVa-VxEod69mUbQ76xERSFWW31c7HrRBlATGmKWEpumJIBqcReqLIBr29rTrXShQ-B8FrOmk8kcHNqGnUTnWKlnlB-BVlLa3vB8~gvU2fohKEBXLp3uGIM08j8-rbruGHBtxpIskUJZxdKeKPAuZ5Yeo88UeyPyGmzRz7UZkeVnDGRdIK~G80ckFurG8td~reMFncB1TJZ5M3ZXOvKu2e2bBWXCZsI7mS0nLk4XSlgJn7i5JsatBh3nlCeHpE52lvMqXiiX2D5fIfjEh-B7NEy2zK6vUBS0D65aTw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Immunotherapy of lymphoma-bearing mice with BsAb directed to Id, MHC II, or CD19 on the tumors.
Groups of 5 huCD64+ age-matched mice received a treatment schedule as shown in Figure 3. Treatment was as indicated: PBS (●); [huCD64 × CD19] (▵); [huCD64 × MHC II] (■); [huCD64 × Id] (○). Survival was recorded daily. In the A31 model all treatment modalities resulted in a statistically significant increase in survival over PBS-treated controls (P < .02), though only [huCD64 × Id] BsAb–treated cohorts showed long-term survival. Similar results were obtained in at least 3 similar experiments.
